{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T00:57:57Z","timestamp":1794272277343,"version":"4.9.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T00:00:00Z","timestamp":1700438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T00:00:00Z","timestamp":1700438400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1007\/s40744-023-00621-6","type":"journal-article","created":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T05:05:26Z","timestamp":1700456726000},"page":"97-112","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Malignancy in the Upadacitinib Clinical Trials for Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis"],"prefix":"10.1007","volume":"11","clinical-trial-number":[{"clinical-trial-number":"nct02706873","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02675426","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02629159","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02706951","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02706847","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03086343","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03104400","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03104374","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03178487","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04169373","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9016-2833","authenticated-orcid":false,"given":"Andrea","family":"Rubbert-Roth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana M.","family":"Kakehasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsutomu","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Schmalzing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Palac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek","family":"Coombs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianzhong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel I.","family":"Anyanwu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph","family":"Lippe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey R.","family":"Curtis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,20]]},"reference":[{"key":"621_CR1","doi-asserted-by":"crossref","unstructured":"Rubbert-Roth A, Kakehasi A, Takeuchi T, et al. Malignancy in the upadacitinib clinical trial programs for rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis [abstract]. Arthritis Rheumatol. 2022;74(suppl 9).","DOI":"10.1007\/s40744-023-00621-6"},{"key":"621_CR2","first-page":"1119","volume":"32","author":"AL Franks","year":"2012","unstructured":"Franks AL, Slansky JE. Multiple associations between a broad spectrum of autoimmune diseases, chronic inflammatory diseases and cancer. Anticancer Res. 2012;32:1119\u201336.","journal-title":"Anticancer Res"},{"key":"621_CR3","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1002\/1097-0215(20001101)88:3<497::AID-IJC27>3.0.CO;2-J","volume":"88","author":"E Thomas","year":"2000","unstructured":"Thomas E, Brewster DH, Black RJ, Macfarlane GJ. Risk of malignancy among patients with rheumatic conditions. Int J Cancer. 2000;88:497\u2013502.","journal-title":"Int J Cancer"},{"key":"621_CR4","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","volume":"295","author":"T Bongartz","year":"2006","unstructured":"Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006;295:2275\u201385.","journal-title":"JAMA"},{"key":"621_CR5","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.3899\/jrheum.100041","volume":"37","author":"MS Krathen","year":"2010","unstructured":"Krathen MS, Gottlieb AB, Mease PJ. Pharmacologic immunomodulation and cutaneous malignancy in rheumatoid arthritis, psoriasis, and psoriatic arthritis. J Rheumatol. 2010;37:2205\u201315.","journal-title":"J Rheumatol"},{"key":"621_CR6","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1159\/000314634","volume":"57","author":"Z Szekanecz","year":"2010","unstructured":"Szekanecz Z, Szekanecz \u00c9, Bak\u00f3 G, Shoenfeld Y. Malignancies in autoimmune rheumatic diseases\u2014a mini-review. Gerontology. 2010;57:3\u201310.","journal-title":"Gerontology"},{"key":"621_CR7","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1186\/s13075-015-0728-9","volume":"17","author":"TA Simon","year":"2015","unstructured":"Simon TA, Thompson A, Gandhi KK, Hochberg MC, Suissa S. Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis. Arthritis Res Ther. 2015;17:212.","journal-title":"Arthritis Res Ther"},{"key":"621_CR8","doi-asserted-by":"crossref","unstructured":"Campanholo CB, Maharaj AB, Corp N, et al. Management of psoriatic arthritis in patients with comorbidities: an updated literature review informing the 2021 GRAPPA treatment recommendations. J Rheumatol. 2023;50(3):426\u201332.","DOI":"10.3899\/jrheum.220310"},{"key":"621_CR9","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1097\/RHU.0000000000000364","volume":"22","author":"KW Hagberg","year":"2016","unstructured":"Hagberg KW, Li L, Peng M, Paris M, Shah K, Jick SS. Rates of cancers and opportunistic infections in patients with psoriatic arthritis compared with patients without psoriatic arthritis. J Clin Rheumatol. 2016;22:241\u20137.","journal-title":"J Clin Rheumatol"},{"key":"621_CR10","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.rdc.2020.04.001","volume":"46","author":"P Karmacharya","year":"2020","unstructured":"Karmacharya P, Shahukhal R, Ogdie A. Risk of malignancy in spondyloarthritis a systematic review. Rheum Dis Clin N Am. 2020;46:463\u2013511.","journal-title":"Rheum Dis Clin N Am"},{"key":"621_CR11","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s41927-022-00275-x","volume":"6","author":"M Bittar","year":"2022","unstructured":"Bittar M, Merjanah S, Alkilany R, Magrey M. Malignancy in ankylosing spondylitis: a cross-sectional analysis of a large population database. BMC Rheumatol. 2022;6:44.","journal-title":"BMC Rheumatol"},{"key":"621_CR12","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2109927","volume":"386","author":"SR Ytterberg","year":"2022","unstructured":"Ytterberg SR, Bhatt DL, Mikuls TR, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. New Engl J Med. 2022;386:316\u201326.","journal-title":"New Engl J Med"},{"key":"621_CR13","first-page":"1","volume":"82","author":"JR Curtis","year":"2022","unstructured":"Curtis JR, Yamaoka K, Chen Y-H, et al. Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial. Ann Rheum Dis. 2022;82:1\u201313.","journal-title":"Ann Rheum Dis"},{"key":"621_CR14","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1016\/S0140-6736(19)30419-2","volume":"393","author":"JS Smolen","year":"2019","unstructured":"Smolen JS, Pangan AL, Emery P, et al. Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase\u00a03 study. Lancet. 2019;393:2303\u201311.","journal-title":"Lancet"},{"key":"621_CR15","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1016\/S0140-6736(18)31116-4","volume":"391","author":"MC Genovese","year":"2018","unstructured":"Genovese MC, Fleischmann R, Combe B, et al. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase\u00a03 trial. Lancet. 2018;391:2513\u201324.","journal-title":"Lancet"},{"key":"621_CR16","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1056\/NEJMoa2008250","volume":"383","author":"A Rubbert-Roth","year":"2020","unstructured":"Rubbert-Roth A, Enejosa J, Pangan AL, et al. Trial of upadacitinib or abatacept in rheumatoid arthritis. N Engl J Med. 2020;383:1511\u201321.","journal-title":"N Engl J Med"},{"key":"621_CR17","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1002\/art.41384","volume":"72","author":"R van Vollenhoven","year":"2020","unstructured":"van Vollenhoven R, Takeuchi T, Pangan AL, et al. Efficacy and safety of upadacitinib monotherapy in methotrexate-naive patients with moderately-to-severely active rheumatoid arthritis (SELECT-EARLY): a multicenter, multi-country, randomized, double-blind, active comparator-controlled trial. Arthritis Rheumatol. 2020;72:1607\u201320.","journal-title":"Arthritis Rheumatol"},{"key":"621_CR18","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1016\/S0140-6736(18)31115-2","volume":"391","author":"GR Burmester","year":"2018","unstructured":"Burmester GR, Kremer JM, Van den Bosch F, et al. Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase\u00a03 trial. Lancet. 2018;391:2503\u201312.","journal-title":"Lancet"},{"key":"621_CR19","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1002\/art.41032","volume":"71","author":"R Fleischmann","year":"2019","unstructured":"Fleischmann R, Pangan AL, Song IH, et al. Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III, double-blind, randomized controlled trial. Arthritis Rheumatol. 2019;71:1788\u2013800.","journal-title":"Arthritis Rheumatol"},{"key":"621_CR20","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1056\/NEJMoa2022516","volume":"384","author":"IB McInnes","year":"2021","unstructured":"McInnes IB, Anderson JK, Magrey M, et al. Trial of upadacitinib and adalimumab for psoriatic arthritis. N Engl J Med. 2021;384:1227\u201339.","journal-title":"N Engl J Med"},{"key":"621_CR21","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1136\/annrheumdis-2020-218870","volume":"80","author":"PJ Mease","year":"2020","unstructured":"Mease PJ, Lertratanakul A, Anderson JK, et al. Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2. Ann Rheum Dis. 2020;80:312\u201320.","journal-title":"Ann Rheum Dis"},{"key":"621_CR22","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1016\/S0140-6736(19)32534-6","volume":"394","author":"D van der Heijde","year":"2019","unstructured":"van der Heijde D, Song IH, Pangan AL, et al. Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase\u00a02\/3 trial. Lancet. 2019;394:2108\u201317.","journal-title":"Lancet"},{"issue":"11","key":"621_CR23","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1136\/ard-2022-222608","volume":"81","author":"D van der Heijde","year":"2022","unstructured":"van der Heijde D, Baraliakos X, Sieper J, et al. Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase\u00a03 trial. Ann Rheum Dis. 2022;81(11):1515\u201323.","journal-title":"Ann Rheum Dis"},{"key":"621_CR24","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/S0140-6736(22)01212-0","volume":"400","author":"A Deodhar","year":"2022","unstructured":"Deodhar A, Van den Bosch F, Poddubnyy D, et al. Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase\u00a03 trial. Lancet. 2022;400:369\u201379.","journal-title":"Lancet"},{"key":"621_CR25","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1002\/art.42250","volume":"74","author":"F Khosrow-Khavar","year":"2022","unstructured":"Khosrow-Khavar F, Desai RJ, Lee H, Lee SB, Kim SC. Tofacitinib and risk of malignancy: results from the safety of tofacitinib in routine care patients with rheumatoid arthritis (STAR-RA) study. Arthritis Rheumatol. 2022;74:1648\u201359.","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"621_CR26","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1002\/acr2.11232","volume":"3","author":"JM Kremer","year":"2021","unstructured":"Kremer JM, Bingham CO, Cappelli LC, et al. Postapproval comparative safety study of tofacitinib and biological disease-modifying antirheumatic drugs: 5-year results from a United States-based rheumatoid arthritis registry. Acr Open Rheumatology. 2021;3(3):173\u201384.","journal-title":"Acr Open Rheumatology"},{"key":"621_CR27","doi-asserted-by":"crossref","unstructured":"Huss V, Bower H, Hellgren K, Frisell T, Askling J. Cancer risks with JAKi and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis or psoriatic arthritis: a national real-world cohort study. Ann Rheum Dis. 2023;82(7):911\u201319.","DOI":"10.1136\/ard-2022-223636"},{"key":"621_CR28","doi-asserted-by":"publisher","first-page":"2855","DOI":"10.1093\/rheumatology\/keac710","volume":"62","author":"L Meudec","year":"2022","unstructured":"Meudec L, Richeb\u00e9 P, Pascaud J, Mariette X, Nocturne G. Janus kinase inhibitors alter NK cell phenotypes and inhibit their antitumour capacity. Rheumatology. 2022;62:2855\u201363.","journal-title":"Rheumatology"},{"key":"621_CR29","doi-asserted-by":"crossref","unstructured":"Fleischmann R, Curtis JR, Charles-Schoeman C, et al. Safety profile of upadacitinib in patients at risk of cardiovascular disease: integrated post hoc analysis of the SELECT phase III rheumatoid arthritis clinical programme. Ann Rheum Dis. 2023;82(9):1130\u201341.","DOI":"10.1136\/ard-2023-223916"},{"key":"621_CR30","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1136\/annrheumdis-2020-218510","volume":"3","author":"SB Cohen","year":"2021","unstructured":"Cohen SB, van Vollenhoven RF, Winthrop KL, et al. Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme. Ann Rheum Dis. 2021;3:304\u201311.","journal-title":"Ann Rheum Dis"},{"key":"621_CR31","unstructured":"AbbVie. RINVOQ\u00ae (upadacitinib) [Prescribing Information]. https:\/\/www.rxabbvie.com\/pdf\/rinvoq_pi.pdf. Accessed 2023 Jul 25."},{"key":"621_CR32","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1136\/annrheumdis-2020-218398","volume":"80","author":"P Nash","year":"2021","unstructured":"Nash P, Kerschbaumer A, D\u00f6rner T, et al. Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. Ann Rheum Dis. 2021;80:71\u201387.","journal-title":"Ann Rheum Dis"},{"key":"621_CR33","unstructured":"Pfizer. XELJANZ\u00ae (tofacitinib) [Prescribing Information]. https:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=959. Accessed 2023 Jul 25."},{"key":"621_CR34","unstructured":"Lilly. OLUMIANT\u00ae (baricitinib) [Prescribing Information]. https:\/\/uspl.lilly.com\/olumiant\/olumiant.html#pi. Accessed 2023 Jul 25."},{"key":"621_CR35","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1111\/bjd.19550","volume":"184","author":"Z Jiyad","year":"2021","unstructured":"Jiyad Z, Marquart L, Green AC. A call to standardize the BCC:SCC ratio. Br J Dermatol. 2021;184:545\u2013545.","journal-title":"Br J Dermatol"},{"key":"621_CR36","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.jaad.2016.08.019","volume":"76","author":"HS Chahal","year":"2017","unstructured":"Chahal HS, Rieger KE, Sarin KY. Incidence ratio of basal cell carcinoma to squamous cell carcinoma equalizes with age. J Am Acad Dermatol. 2017;76:353\u20134.","journal-title":"J Am Acad Dermatol"},{"key":"621_CR37","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/j.mayocp.2017.02.015","volume":"92","author":"JG Muzic","year":"2017","unstructured":"Muzic JG, Schmitt AR, Wright AC, et al. Incidence and trends of basal cell carcinoma and cutaneous squamous cell carcinoma a population-based study in Olmsted county, Minnesota, 2000 to 2010. Mayo Clin Proc. 2017;92:890\u20138.","journal-title":"Mayo Clin Proc"},{"key":"621_CR38","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1158\/1078-0432.CCR-18-1122","volume":"25","author":"P Nagarajan","year":"2019","unstructured":"Nagarajan P, Asgari MM, Green AC, et al. Keratinocyte carcinomas: current concepts and future research priorities. Clin Cancer Res. 2019;25:2379\u201391.","journal-title":"Clin Cancer Res"},{"key":"621_CR39","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s12325-019-01130-1","volume":"37","author":"OT Jones","year":"2020","unstructured":"Jones OT, Ranmuthu CKI, Hall PN, Funston G, Walter FM. Recognising skin cancer in primary care. Adv Ther. 2020;37:603\u201316.","journal-title":"Adv Ther"},{"key":"621_CR40","doi-asserted-by":"publisher","first-page":"62","DOI":"10.7861\/clinmedicine.16-1-62","volume":"16","author":"LL Griffin","year":"2016","unstructured":"Griffin LL, Ali FR, Lear JT. Non-melanoma skin cancer. Clin Med. 2016;16:62\u20135.","journal-title":"Clin Med"},{"key":"621_CR41","doi-asserted-by":"publisher","first-page":"339","DOI":"10.5694\/mja17.00284","volume":"207","author":"N Pandeya","year":"2017","unstructured":"Pandeya N, Olsen CM, Whiteman DC. The incidence and multiplicity rates of keratinocyte cancers in Australia. M\u00e9d J Aust. 2017;207:339\u201343.","journal-title":"M\u00e9d J Aust"},{"key":"621_CR42","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1007\/s10067-016-3396-5","volume":"35","author":"KM Wilton","year":"2016","unstructured":"Wilton KM, Crowson CS, Matteson EL. Malignancy incidence in patients with psoriatic arthritis: a comparison cohort-based incidence study. Clin Rheumatol. 2016;35:2603\u20137.","journal-title":"Clin Rheumatol"},{"key":"621_CR43","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41568-019-0222-9","volume":"20","author":"M Fane","year":"2020","unstructured":"Fane M, Weeraratna AT. How the ageing microenvironment influences tumour progression. Nat Rev Cancer. 2020;20:89\u2013106.","journal-title":"Nat Rev Cancer"},{"key":"621_CR44","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.canlet.2008.01.009","volume":"261","author":"TM Oberyszyn","year":"2008","unstructured":"Oberyszyn TM. Non-melanoma skin cancer: Importance of gender, immunosuppressive status and vitamin D. Cancer Lett. 2008;261:127\u201336.","journal-title":"Cancer Lett"},{"key":"621_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.26444\/aaem\/94299","volume":"26","author":"AM Lewandowska","year":"2018","unstructured":"Lewandowska AM, Rudzki M, Rudzki S, Lewandowski T, Laskowska B. Environmental risk factors for cancer\u2014review paper. Ann Agric Environ Med. 2018;26:1\u20137.","journal-title":"Ann Agric Environ Med"},{"key":"621_CR46","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/291546","volume":"2013","author":"GD Pergola","year":"2013","unstructured":"Pergola GD, Silvestris F. Obesity as a major risk factor for cancer. J Obes. 2013;2013: 291546.","journal-title":"J Obes"}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-023-00621-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-023-00621-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-023-00621-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T10:32:11Z","timestamp":1705573931000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-023-00621-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,20]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["621"],"URL":"https:\/\/doi.org\/10.1007\/s40744-023-00621-6","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,20]]},"assertion":[{"value":"25 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Financial arrangements of the authors with companies whose products may be related to the present manuscript are listed, as declared by the authors. Andrea Rubbert-Roth: Received honoraria for lectures and consulting from AbbVie, Amgen, BMS, Eli Lilly, Gilead, Janssen, MSD, Novartis, Pfizer, Roche, Sanofi, and UCB. Adriana M. Kakehasi: Served as a consultant or member of a speaker\u2019s bureau for, and has received grant\/research support from, AbbVie, Amgen, Fresenius Klabi, Janssen, Eli Lilly, Pfizer, Organon, Sandoz, and UCB. Tsutomu Takeuchi: Grant\/research support from AbbVie and Eisai; consulting fees from AbbVie, Astellas Pharma, Eli Lilly Japan, and Gilead Sciences; speaker\/honoraria from AbbVie, Astellas Pharma, Eisai, Eli Lilly Japan, Gilead Sciences, and Pfizer Japan. Marc Schmalzing: Compensation for consulting from Chugai\/Roche, Hexal\/Sandoz, Gilead, AbbVie, Janssen-Cilag, Boehringer\/Ingelheim, onkowissen.de, EUSA-Pharma, Novartis, AstraZeneca, Amgen, Medac, Lilly, and Galapagos; speaker\u2019s fees from Novartis, AbbVie, AstraZeneca, Chugai\/Roche, Janssen-Cilag, Gilead, Boehringer\/Ingelheim, Mylan, Galapagos, and EUSA-Pharma; travel grants from Chugai\/Roche, Boehringer\/Ingelheim, Celgene, Medac, UCB, Mylan, and Galapagos. Hannah Palac: Employee of AbbVie and may hold stock or stock options. Derek Coombs: Employee of AbbVie and may hold stock or stock options. Jianzhong Liu: Employee of AbbVie at time of study and has since retired. May hold stock or stock options in Abbvie. Samuel I. Anyanwu: Employee of AbbVie and may hold stock or stock options. Ralph Lippe: Employee of AbbVie and may hold stock or stock options. Jeffrey R. Curtis: Research grants from AbbVie, Amgen, Bristol Myers Squibb, CorEvitas, Janssen, Labcorp, Lilly, Novartis, Pfizer, Sanofi\/Regeneron, and UCB; consulting fees from AbbVie, Amgen, Bristol Myers Squibb, CorEvitas, Janssen, Labcorp, Lilly, Novartis, Pfizer, Sanofi\/Regeneron, and UCB.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All studies were conducted in accordance with the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines, applicable regulations governing clinical trial conduct, and the Declaration of Helsinki 1964 and its later amendments. The trial protocols were approved by an independent ethics committee (IEC)\/institutional review board (IRB) at each study site per Good Clinical Practice (GCP). All patients provided written informed consent prior to screening.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}